<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100543'>Cognitive impairment</z:hpo> is the primary symptom of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) </plain></SENT>
<SENT sid="1" pm="."><plain>Animal and human studies indicate that, as with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), deficits in cholinergic transmission -- including nicotinic receptor binding abnormalities -- may be responsible for the development of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> associated with VaD </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, studies of <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitors</z:chebi> (AChEIs) have been initiated and have shown promising results to date </plain></SENT>
<SENT sid="3" pm="."><plain>These agents have demonstrated cognitive and global benefits in patients with VaD </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, functional and behavioral benefits have been reported with the dual-mechanism AChEI galantamine </plain></SENT>
<SENT sid="5" pm="."><plain>These studies suggest a potential role for AChEIs in the management of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> associated with VaD </plain></SENT>
</text></document>